The rapid antidepressant action of the glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has kindled great interest and optimism among researchers, clinicians and patients. Both open-label studies and small randomised controlled trials (RCTs) in treatment-resistant unipolar or bipolar depression have shown antidepressant effects occurring within hours of intravenous (i.v.) infusion with ketamine. This supports the idea that, besides the monoaminergic systems, the glutamatergic system may also be targeted for the treatment of major depressive disorder (MDD). In patients with mood disorders, glutamate levels in the serum and cerebrospinal fluid are altered. Ketamine increases the presynaptic release of glutamate, resulting in higher extracellular levels of glutamate by a combination of disinhibition of the neurotransmitter γ-aminobutyric acid (GABA) and blockage of the NMDA receptors at the phencyclidine binding site within the ion channel. This increase in extracellular glutamate release favours coexpressed α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), resulting in an increased glutamatergic throughput of AMPA relative to NMDA. The glutamatergic system is also fundamental for neuroplasticity, which is linked to mood disorders. NMDA receptor activation is part of the induction process for long-term potentiation, an important form of synaptic plasticity. Synapse-associated proteins and the number of dendritic spines then increase, for example, in the prefrontal cortex, thus reversing the structural and functional deficits resulting from long-term stress exposure.

In treatment-resistant unipolar or bipolar depression studies, ketamine has mostly been administered intravenously. A rapid i.v. infusion of ketamine for treatment-resistant unipolar or bipolar depression, usually at a dose of 0.5 mg/kg, leads to an immediate bioavailability of 100%. To date, six double-blind, crossover RCTs have been published that compared a single dose of i.v. ketamine with placebo. (Five of them used an inactive placebo – saline and one used an active placebo – midazolam.) Overall, these studies showed rapid initial effects (40 min after infusion) that increase to 1 day post-infusion, but overall the difference between ketamine and placebo (inactive or active) was no longer statistically significant at 7 days post-infusion. A recent open-label study that compared ketamine with active placebo (midazolam) had a similar effect size of 0.81 at 1 day post-infusion, but again the effect did not last. The great challenge with ketamine as an antidepressant is to extend its duration of action.

To study the efficacy of repeated ketamine infusions, a non-blind study provided six infusions over 2 weeks. After the last infusion, 8 of 9 patients (89%) were in remission. The average time to relapse after the last infusion was much longer than in single injection studies: 19 days (s.d. = 13) after the last infusion. Investigators reported no worsening of cognitive function during the follow-up period although this was not formally tested. Other researchers have sought to maintain the effect of i.v. ketamine by adding oral riluzole, a glutamatergic modulator with antidepressant and synaptic plasticity-enhancing effects, but this was unsuccessful. Future research should then explore new strategies to optimise the antidepressant response, including dosing regimens and routes of administration.

To date, the field of psychiatry has paid little attention to the experience with oral and other non-intravenous administrations of ketamine for chronic pain. Ketamine is a well-known anaesthetic, with analgesic effects that may be used to treat chronic pain in a range of disorders. In the field of pain management, there is ample experience with the oral as well as i.v. application of ketamine.
Indications for oral ketamine include neuropathic pain of various origins, complex regional pain syndrome, cancer pain, orofacial pain and phantom limb pain. As in depression, the therapeutic effect is believed to be based on antagonism of the NMDA receptor.20

This review describes the findings of these studies and combines the fields of pain management and depression, with special attention to safety, dosing regimen and treatment duration.

**Method**

We searched PubMed with the following terms: ‘oral ketamine’ AND ‘depression’; ‘oral ketamine’ AND ‘chronic pain’ OR ‘neuropathic pain’; ‘intravenous ketamine’ AND ‘depression’; ‘intravenous ketamine’ AND ‘chronic pain’ OR ‘neuropathic pain’; ‘intranasal ketamine’ AND ‘depression’; ‘intranasal ketamine’ AND ‘chronic pain’ OR ‘neuropathic pain’; and ‘subcutaneous ketamine’ AND ‘depression’ and ‘subcutaneous ketamine’ AND ‘chronic pain’ OR ‘neuropathic pain’ (final search date 27 October 2014). Our searches yielded 112 studies. We excluded literature reviews, studies with animals and studies with healthy individuals, thereby yielding 88 studies. We scanned all papers for information about study type and size, dosing regimen, number of individuals who received ketamine, number of ketamine days per study, results and side-effects. When these were described, we entered them into two tables (both available online). Table DS1 refers to the studies where ketamine was used to treat depression and Table DS2 refers to the studies where ketamine was used to treat pain. We designed two graphs with the information provided by those tables (Figs 1 and 2).

In total, for depression 4 studies were found using oral ketamine (n = 22), 43 studies used intravenous ketamine (n = 763), 2 studies used intranasal ketamine (n = 19), 1 study used sublingual ketamine (n = 26), and 2 case reports concerned intramuscular ketamine (n = 3). For pain, 12 studies used oral (n = 76), 21 studies intravenous (n = 553), 2 studies intranasal (n = 21) and 1 study intramuscular ketamine (n = 35). We found only one study on subcutaneous ketamine for pain that met the inclusion criteria, but it presented insufficient data (no dose and no number of ketamine days described), so we excluded it from the analysis. We found no subcutaneous ketamine for depression study. One sublingual ketamine for depression study and three intramuscular ketamine studies (one for pain and two for depression) were included in our analysis.

To compare dosing regimens across studies, we calculated the daily oral racemate equivalent dose, in mg/kg/day, by multiplying the i.v. dose by five to correct for the five times lower oral bioavailability21,22 and by multiplying the (S)-ketamine dose by two to correct for the double potency relative to racemate. For intranasal dosing regimens, we obtained the daily oral racemate equivalent dose by multiplying them by 2.25 to correct for the 2.25 times lower oral bioavailability.23 In the case of intramuscular dosing regimens, we calculated the daily oral racemate equivalent dose by multiplying them by 4.65 to correct for the 4.65 times lower oral bioavailability.21 We multiplied the sublingual dose by 1.5 to obtain their daily oral racemate equivalent dose.23

**Results**

**Oral ketamine for depression**

Five uncontrolled, open-label studies were found that investigated the antidepressant properties of oral (including sublingual) ketamine.24–28 A small study (n = 4) found depression relief in patients with treatment-resistant unipolar or bipolar depression who were given up to 1.25 mg/kg oral (S)-ketamine for 2 weeks.24 In one study on palliative healthcare,25 the effects of ketamine on pain, anxiety and depression were assessed. This case report described a hospice patient who was treated daily with 40 mg oral ketamine, which relieved all three complaints. Another hospice-based study described two severely ill and depressed patients who showed significant improvements lasting 1 or 2 weeks after a single oral dose of 0.5 mg/kg ketamine.26 A more recent
hospice-based study administered daily oral ketamine (0.5 mg/kg) over a 28-day period to patients in hospice care who had depressive symptoms. Eight out of 14 patients completed the trial and showed significant improvement in pain and depression with few side-effects. De Gioannis & De Leo treated two patients with chronic suicidal ideation (and at least two significant past suicide attempts) with a solution of ketamine ingested with a flavoured drink. The maximum dose used was 3 mg/kg of ketamine. Both patients achieved sustained remission from suicidal ideation.

Lara et al reported on 10 mg sublingual ketamine, administered once, or every 2, 3 or 7 days for a total of up to 20 doses. They observed improved mood in 20 out of 26 patients with treatment-resistant unipolar or bipolar depression. The antidepressant effects outlasted the acute side-effects, which primarily concerned light-headedness, and which did not include euphoria or dissociation.

Clearly, these are only first indications of possible antidepressant effects of oral ketamine, as all of these studies were very small and uncontrolled, and the quality of the evidence was low.

### Dosing regimen and treatment duration of ketamine in chronic pain

Figures 1 and 2 show that both for depression and pain most studies used the i.v. route of application. Expressed in daily oral racemate equivalent dose, the doses for depression are in the lower range compared with studies that investigated analgesic use. Also, the graphs show that ketamine as an antidepressant is generally given for shorter durations (1–32 days) than ketamine as an analgesic. Finally, it shows that on average i.v. ketamine is given for a shorter duration than oral ketamine. Studies with oral ketamine, where pain was the primary indication, administered ketamine once or for as long as 660 days, with most studies in the range of 20–80 days. The doses used in the pain studies we analysed differed from the 0.1 daily oral racemate equivalent dose via oral administration to 62.5 mg/kg/day intravenously. It is not possible to establish a dose–response association, but the majority of the pain studies we analysed describe ketamine as effective in reducing pain, even with low oral doses. The exceptions are six studies that used i.v. ketamine, which did not lead to any reduction in the pain scores. Although the study conducted by Kapural et al used a high dose (daily oral racemate equivalent dose of 21.5 mg/kg/day), it did not achieve an improvement in long-term pain scores in patients with high opioid requirements.

Some studies in patients with chronic pain (that could be progressive or related to terminal illness) showed that patients required higher doses over time. For instance, Villanueva-Perez et al administered 30 mg of oral ketamine every 8 hours to a patient with complex regional pain syndrome type 1, increasing this dose weekly by 5 mg until a maximum dose of 60 mg/6 h was reached. This patient kept this last dose for more than 2 years with significant improvement mainly in the first 17 months. Vick & Lamer achieved significant improvement in pain, allodynia and hyperalgesia in one patient with central post-stroke pain at a dose of 50 mg oral ketamine three times per day. This treatment lasted 3 months.

Clearly, the dosage is directly related to the bioavailability of ketamine. With oral administration the bioavailability is generally low, because of extensive first-pass metabolism. Reported values of oral ketamine in adults are in the range of 17–24%. A study by Brunette et al in children showed the highest bioavailability (45%), and used a nasogastric tube and a 10 mL water flush, but Tanagihara et al also used a water flush (100 mL) and found a bioavailability of only 20% in adults. Other factors underlying the variability after oral dosing may include the formulation (tablet or solution, ketamine concentration), state of the stomach, dietary enzyme induction, and individual differences in cytochrome phenotype. It should be noted that interindividual pharmacokinetic variability is common to oral administration in general and has also been described for currently prescribed antidepressants. Intranasal and sublingual ketamine administration
have been reported to yield 45% and 30% bioavailability, respectively, but interindividual variability has been described for these routes of ketamine administration as well. Ketamine absorption after intramuscular injection has been described as more rapid, with a bioavailability of 93%. Safety and abuse potential

The most common side-effects of i.v. ketamine are psycho-mimetic effects and dissociative symptoms, which correlate with high initial plasma levels and may thus be less pronounced in oral administration. Feeling 'high' after ketamine is also dependent on plasma levels. Other known side-effects are confusion, dizziness, euphoria, elevated blood pressure and increased libido, although all of these usually dissipate within 2 h of i.v. infusion. Ketamine neurotoxicity has been described in preclinical studies, but this was suggested to be due to the presence of the preservative chlorobutanol rather than to the ketamine itself. Without preservative, ketamine can induce neurotoxicity when injected in very high doses into the subarachnoid space. The study by Sun et al showed that i.v. ketamine given to adolescent cynomolgus monkeys at a dose of 1 mg/kg in saline for 6 months might also produce permanent and irreversible deficits in brain function through the neurotoxic effect caused by the activation of the apoptotic pathway in the prefrontal cortex. This appears to be in contrast with studies in humans where ketamine was given in similar or higher doses with few mentions of cognitive problems. It should be noted that currently available clinical studies with i.v. ketamine used only one or few applications. In the studies involving pain, patients were given ketamine more often but mostly did not have the 'peak effect' of i.v. application. Prolonged ketamine misuse has been associated with white matter changes, memory changes, neurocognitive impairment, and reduced well-being. Finally, inflammation and damage to the ureter and bladder are well documented in very heavy ketamine users who consume daily amounts of 1 g by inhalation and for prolonged periods of months or even years. Notably, in these studies daily doses were substantially higher than those used in clinical studies. Calculated in daily oral racemate equivalent dose, these users had approximately 80 mg/kg/day, which is 2.2 times higher than the highest daily oral racemate equivalent dose found in a study where ketamine was used to treat depression.

The majority of the pain and depression studies retrieved by our search did not report the side-effects of oral ketamine as a major burden in treatment maintenance. Side-effects commonly mentioned were: dizziness, hallucinations, nausea, vomiting, drowsiness, confusion, light-headedness, headache, somnolence and anxiety. An exception to this is the study by Kannan et al involving nine patients with neuropathic pain, which stated that the beneficial effects in the management of intractable neuropathic pain were limited in some patients by adverse events such as nausea, vomiting, loss of appetite, drowsiness, sedation and feeling of unreality. Haines & Gaines found that ketamine caused an analgesic response in only 14% of individuals and described that the adverse events (light-headedness, dizziness, tiredness, headache, nervous floating feeling and bad dreams) limited the use of ketamine in almost half of their patients. Side-effects commonly mentioned in studies using oral ketamine were light-headedness or dizziness, nausea, vomiting, drowsiness, confusion, headache, somnolence, and having bad dreams. Hallucinations and paranoid feelings were reported in only one patient, and memory impairment and dysuria were reported in one study on 12 patients.

Very-low-dose sublingual administration of 10 mg (approximately equivalent to 0.036 mg/kg i.v.) was not associated with euphoria, or psychotic and dissociative symptoms. In some studies, increased blood pressure was recorded when a benzodiazepine was administered concomitantly. The reported adverse events were usually limited to the ketamine treatment phase and did not persist after ketamine discontinuation (see online Tables DS1 and DS2 for more details on these side-effects).

Another concern with ketamine is its misuse potential, which has been demonstrated in both animals and humans. Ketamine has been used as a street drug since the 1960s, probably because of its rapid effects, its low cost and its specific psychotropic effects, such as hallucinatory and dissociative experiences (e.g. ‘melting into the surrounding’, ‘out-of-body experiences’) as well as ‘giggliness’. Multi-drug users who have used ketamine in large doses recreationally have also expressed concerns about its addictive properties. No studies compared different routes of ketamine administration directly, but the misuse potential is generally found to be higher with i.v. administration or inhalation that produces much more rapid and intensive effects compared to oral administration. In line with this, the psychedelic effects of ketamine are directly related to plasma concentrations. Importantly, in the pain studies mentioned earlier, addiction or misuse were not described as side-effects. Still, it is clear that these unwanted effects should be balanced against the possible beneficial properties of ketamine. Overall, the results suggest that oral ketamine in the described doses may be well tolerated. However, few studies have systematically studied its possible longer-term consequences. In comparison with studies of patients with pain, treatment duration in the currently available studies of depression is at the lower end of the spectrum. Further research is needed including basic science, acceptability and feasibility studies, ethical perspectives, and ultimately building to randomised trial designs. A number of issues need to be addressed. First, ketamine raises concerns, such as its potential for misuse, that warrant solid monitoring. Even though our review did not show such problems to be very important in studies on depression and pain, this may be much more of a problem if ketamine were to be used on a broader basis in clinical practice. We fully agree with the cautionary note of Schatzberg, who has signalled growing use without good evidence underlying it. It is also in line with the recent Cochrane review by Caddy et al that states that there is a need for studies examining the longer-term effects of repeated use of ketamine that also take into account oral and intramuscular routes. Both the short- and longer-term therapeutic effects as well as the possible side-effects of longer treatment duration of ketamine should be thoroughly assessed and reported before this could be applied on any scale in clinical practice.

Second, even though the side-effect profile of oral ketamine seems to be milder than that reported in i.v. studies and in severe drug misusers, the overall safety profile would warrant that ketamine should be provided within a hospital setting. After an initial in-patient phase, oral ketamine might, however, be prescribed to depressed patients outside of the hospital environment for maintenance purposes, depending on an assessment of risk for each individual patient. Furthermore, side-effects should systematically be monitored using an instrument such as the Systematic Assessment for Treatment Emergent Events.

Third, oral bioavailability of ketamine is rather low and variable, and studies should take into account blood levels and ketamine formulation. Fourth, as the antidepressant effects of ketamine may partially be related to its anaesthetic potential,
especially in depressed patients with pain, a thorough assessment of both depressive symptoms and pain needs to be incorporated into upcoming trials.

Based on the above, we believe it is time to conduct rigorous RCTs that determine the benefits as well as possible unsolicited consequences of oral ketamine, given for weeks rather than days, for patients with treatment-resistant depression.

References


62 Freeman TP, Morgan CJ, Pepper F, Howes OD, Stone JM, Curran HV. Associative blocking to reward-predicting cues is attenuated in ketamine users but can be modulated by images associated with drug use. Psychopharmacology (Berl) 2013; 225: 41–50.


https://doi.org/10.1192/bjp.bp.115.165498 Published online by Cambridge University Press